Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Open accessThe DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
Leber's congenital amaurosis (LCA) is a group of inherited blinding diseases with onset during childhood. One form of the disease, LCA2, is caused by mutations in the retinal pigment epithelium-specific 65-kDa protein gene (RPE65). We investigated the safety of subretinal delivery of a recombinant adeno-associated virus (AAV) carrying RPE65 complementary DNA (cDNA) (ClinicalTrials.gov number, NCT00516477 [ClinicalTrials.gov]). Three patients with LCA2 had an acceptable local and systemic adverse-event profile after delivery of AAV2.hRPE65v2. Each patient had a modest improvement in measures of retinal function on subjective tests of visual acuity. In one patient, an asymptomatic macular hole developed, and although the occurrence was considered to be an adverse event, the patient had some return of retinal function. Although the follow-up was very short and normal vision was not achieved, this study provides the basis for further gene therapy studies in patients with LCA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The main disadvantage of this approach is the surgery itself. Traditional vitrectomy complications such as cataract, IOP rise and retinal tears, as well as subretinal injection-related complications such as a macular hole.4,87,88”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [88]
In the citing paper
“Many current retinal gene therapy trials adopt a standardized immunosuppression protocol up to 21 days post-treatment, which may ameliorate this immune response in humans.6,7,40”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [40]
In the citing paper
“Despite a 28-day oral corticosteroid therapy started 2 days before the first IVT, a regimen similar to that provided in several other clinical studies using IVT or sub-retinal AAV-based gene therapies,41–45 70.7% of lenadogene nolparvovec-treated eyes developed some degree of intraocular inflammation versus 10.2% of placebo-treated eyes.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [42]
In the citing paper
“during Phase I/II clinical trials for Leber's congenital amaurosis (LCA), over 30 patients who received a subretinal injection of AAV2 encoding RPE65, an enzyme responsible for the isomerohydrolase activity of retinal pigment epithelium, showed sustained improvement in both subjective and objective measurements of vision.8–14”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [11]
In the citing paper
“As a result, AAV clinical successes to date have involved delivery either to immune privileged regions or to subjects lacking apparent AAV immunological memory.8–14,30,42”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [11]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Self-citationIdiopathic Senile Macular Hole: Its Early Stages and Pathogenesis
Gass, J. D. M. (1988) · Archives of Ophthalmology · doi:10.1001/archopht.1988.01060130683026 · Cited by 992
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Self-citationMutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663
RPE65 is the isomerohydrolase in the retinoid visual cycle
Moiseyev, G., Chen, Y., Takahashi, Y., Wu, B. X., & Ma, J.-X. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503460102 · Cited by 536
Self-citationAcland, G. M., Aguirre, G. D., Bennett, J., Aleman, T. S., Cideciyan, A. V., Bennicelli, J., Dejneka, N. S., Pearce-Kelling, S. E., Maguire, A. M., Palczewski, K., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.008 · Cited by 477
Self-citationRpe65 is the retinoid isomerase in bovine retinal pigment epithelium
Jin, M., Li, S., Moghrabi, W. N., Sun, H., & Travis, G. H. (2005) · Cell · doi:10.1016/j.cell.2005.06.042 · Cited by 424
Redmond, T. M., Poliakov, E., Yu, S., Tsai, J.-Y., Lu, Z., & Gentleman, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504167102 · Cited by 409
Self-citationNatural Course of Retinitis Pigmentosa Over a Three-Year Interval
Berson, E. L., Sandberg, M. A., Rosner, B., Birch, D. G., & Hanson, A. H. (1985) · American Journal of Ophthalmology · doi:10.1016/0002-9394(85)90351-4 · Cited by 321
Jacobson, S. G., Aleman, T. S., Cideciyan, A. V., Sumaroka, A., Schwartz, S. B., Windsor, E. A. M., Traboulsi, E. I., Heon, E., Pittler, S. J., Milam, A. H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500646102 · Cited by 274
Self-citation
Research works printed but not linked: 4
- Lorenz B, 2000, Invest Ophthalmol Vis Sci, 41, 2735
- Aguirre GD, 1998, Mol Vis, 4, 23
- 10.1038/88327 · DOI
- Fosnaugh JS, 1992, Methods Find Exp Clin Pharmacol, 14, 545
Cited by
Items 601–700 of 1,031
The CRB1 Complex: Following the Trail of Crumbs to a Feasible Gene Therapy Strategy
Quinn, P. M. J., Pellissier, L. P., & Wijnholds, J. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00175 · Cited by 62
“Current clinical trials for the RPE65, REP1, and CNGA3 genes have revealed both the effectiveness and limitations associated with retinal gene therapy, including the timing, injection method, and transduction coverage (Bainbridge et al., 2015; Edwards et al., 2016; Fischer et al., 2016; https://clinicaltrials.gov; Mag…”
BackgroundPetersen‐Jones, S. M., Occelli, L. M., Winkler, P. A., Lee, W., Sparrow, J. R., Tsukikawa, M., Boye, S. L., Chiodo, V. A., Capasso, J. E., Bećirović, E., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci95161 · Cited by 63
Ramlogan‐Steel, C. A., Murali, A., Andrzejewski, S., Dhungel, B., Steel, J. C., & Layton, C. J. (2019) · Clinical & Experimental Ophthalmology · doi:10.1111/ceo.13416 · Cited by 57
“The reasons for the lack of longevity in these early trials are unclear but it was noted that the decline after initial improvement was associated with vectors that were driven using a cell-specific retinal pigment epithelium (RPE) promoter, while in other trials for LCA, a ubiquitous CBA promoter was used in the vect…”
BackgroundMaterials promoting viral gene delivery
Kaygisiz, K., & Synatschke, C. V. (2020) · Biomaterials Science · doi:10.1039/d0bm01367f · Cited by 59
Host immune responses after suprachoroidal delivery of AAV8 in nonhuman primate eyes
Chung, S. H., Mollhoff, I. N., Mishra, A., Sin, T.-N., Ngo, T., Ciulla, T., Sieving, P., Thomasy, S. M., & Yiu, G. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.281 · Cited by 57
Jo, D. H., Koo, T., Cho, C. S., Kim, J. H., Kim, J.-S., & Kim, J. H. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.10.009 · Cited by 57
A versatile toolkit for overcoming AAV immunity
Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991832 · Cited by 57
“Then, Luxturna, an AAV2-based gene therapy for retinal diseases (8), was approved in the USA in 2017, and Zolgensma, an AAV9-based gene therapy for spinal muscular atrophy in the USA in 2019 (9).”
MethodThe gene therapy journey for hemophilia: are we there yet?
High, K. A. (2012) · Blood · doi:10.1182/blood-2012-05-423210 · Cited by 55
Self-citationLow Vision and Plasticity: Implications for Rehabilitation
Legge, G. E., & Chung, S. T. L. (2016) · Annual Review of Vision Science · doi:10.1146/annurev-vision-111815-114344 · Cited by 63
“…pathway, such as those found in albinism, appear to be irreversible, although the possibility of treating inherited disorders such as Leber’s congenital amaurosis (a form of retinitis pigmentosa) with gene therapy is being studied (Bainbridge et al. 2008, Maguire et al. 2008, Jacobson et al. 2015).”
Re-analysis of genomic data: An overview of the mechanisms and complexities of clinical adoption
Robertson, A. J., Tan, N. B., Spurdle, A. B., Metke‐Jimenez, A., Sullivan, C. M., & Waddell, N. (2022) · Genetics in Medicine · doi:10.1016/j.gim.2021.12.011 · Cited by 72
Chien, Y., Hsiao, Y.-J., Chou, S.-J., Lin, T.-Y., Yarmishyn, A. A., Lai, W.-Y., Lee, M.-S., Lin, Y.-Y., Lin, T.-W., Hwang, D.-K., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01717-x · Cited by 57
Tzameret, A., Sher, I., Belkin, M., Treves, A. J., Meir, A., Nagler, A., Levkovitch-Verbin, H., Rotenstreich, Y., & Solomon, A. (2015) · Stem Cell Research · doi:10.1016/j.scr.2015.08.007 · Cited by 59
Two-photon microscopy reveals early rod photoreceptor cell damage in light-exposed mutant mice
Maeda, A., Palczewska, G., Golczak, M., Kohno, H., Dong, Z., Maeda, T., & Palczewski, K. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317986111 · Cited by 57
Retinal Ganglion Cell Gene Therapy and Visual System Repair
Hellström, M., & Harvey, A. R. (2011) · Current Gene Therapy · doi:10.2174/156652311794940746 · Cited by 60
“rAAV vectors encoding RPE65 have recently been trialled in patients with Leber’s congenital amaurosis (LCA) with promising outcomes [2, 3, 5, 78] and progress is being made towards novel gene therapeutic solutions for patients with retinitis pigmentosa [79].”
BackgroundInfluentialNanocarriers of nanotechnology in retinal diseases
Al-Halafi, A. M. (2014) · Saudi Journal of Ophthalmology · doi:10.1016/j.sjopt.2014.02.009 · Cited by 62
Synthesis and Characterization of Glycol Chitosan DNA Nanoparticles for Retinal Gene Delivery
Mitra, R. N., Han, Z., Merwin, M., Al Taai, M., Conley, S. M., & Naash, M. I. (2014) · ChemMedChem · doi:10.1002/cmdc.201300371 · Cited by 56
Lea, D. H., Skirton, H., Read, C. Y., & Williams, J. K. (2010) · Journal of Nursing Scholarship · doi:10.1111/j.1547-5069.2010.01373.x · Cited by 57
“In patients whose LCA is caused by a mutation in the RPE65 gene, insertion of the nonmutated gene using an adenovirus vector resulted in some improvement in vision (Maguire et al., 2008).”
BackgroundCRB1 : One Gene, Many Phenotypes
Ehrenberg, M., Pierce, E. A., Cox, G. F., & Fulton, A. B. (2013) · Seminars in Ophthalmology · doi:10.3109/08820538.2013.825277 · Cited by 70
Self-citationSharma, T. P., Wiley, L. A., Whitmore, S. S., Anfinson, K. R., Cranston, C. M., Oppedal, D. J., Daggett, H. T., Mullins, R. F., Tucker, B. A., & Stone, E. M. (2017) · Stem Cell Research · doi:10.1016/j.scr.2017.03.005 · Cited by 57
Self-citationGene therapy in inherited retinal degenerative diseases, a review
Takahashi, V. K. L., Takiuti, J. T., Jauregui, R., & Tsang, S. H. (2018) · Ophthalmic Genetics · doi:10.1080/13816810.2018.1495745 · Cited by 57
“different dosages of the delivered vector(23,24).”
Brydon, E. M., Bronstein, R., Buskin, A., Lako, M., Pierce, E. A., & Fernandez-Godino, R. (2019) · doi:10.1101/729160 · Cited by 56
Self-citationBrydon, E. M., Bronstein, R., Buskin, A., Lako, M., Pierce, E. A., & Fernandez-Godino, R. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.10.014 · Cited by 53
Self-citationTask-Dependent V1 Responses in Human Retinitis Pigmentosa
Masuda, Y., Horiguchi, H., Dumoulin, S. O., Furuta, A., Miyauchi, S., Nakadomari, S., & Wandell, B. A. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-4775 · Cited by 68
Palfi, A., Millington-Ward, S., Chadderton, N., O'Reilly, M., Goldmann, T., Humphries, M. M., Li, T., Wolfrum, U., Humphries, P., Kenna, P. F., et al. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.119 · Cited by 56
Endoglin: a critical mediator of cardiovascular health
Kapur, N. K., Morine, K., & Letarte, M. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s29144 · Cited by 69
“Whether future therapies such as gene transfer methods can target the underlying genetic defect associated with HHT remains unknown.(81,82) Further insight into the role of endoglin and the TGFβ signaling pathway in the pathogenesis of HHT, together with evolving molecular approaches, may lead to novel therapeutic app…”
Neurological Basis for Eye Movements of the Blind
Schneider, R. M., Thurtell, M. J., Eisele, S., Lincoff, N., Bala, E., & Leigh, R. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056556 · Cited by 56
“It will be interesting to study how well voluntary ocular motor control returns in patients with Leber’s congenital amaurosis following vision restoration with gene therapy [50].”
BackgroundMesenchymal stem cells, cancer challenges and new directions
Serakıncı, N., Fahrioğlu, U., & Christensen, R. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.02.011 · Cited by 56
“With regard to local delivery of the therapeutic transgene to neighbouring cancer cells scientists are always developing creative and more effective ways of providing the gene delivery to target cells [71–75].”
BackgroundAdeno-Associated Virus Vector for Central Nervous System Gene Therapy
Zhu, D., Schieferecke, A. J., Lopez, P. A., & Schaffer, D. V. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.03.010 · Cited by 56
Askou, A. L., Pournaras, J. C., Pihlmann, M., Svalgaard, J. D., Arsenijevic, Y., Kostic, C., Bek, T., Dagnæs‐Hansen, F., Mikkelsen, J. G., Jensen, T. G., et al. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.2678 · Cited by 55
Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates
Lai, C.-M., Estcourt, M. J., Himbeck, R. P., Lee, S.-Y., Yeo, I., Luu, C. D., Loh, B. K., Lee, M. W., Barathi, V. A., Villano, J., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.169 · Cited by 60
Hellström, M., Pollett, M. A., & Harvey, A. R. (2011) · Journal of Neurotrauma · doi:10.1089/neu.2011.1928 · Cited by 55
“…has resulted in a gain of visual function in patients with the inherited blinding disease Leber’s congenital amaurosis (Bainbridge et al., 2008; Maguire et al., 2008). rAAV encoding appropriate transgenes may also be of use in the treatment of progressive neurodegenerative diseases such as…”
Tyrosine-Mutant AAV8 Delivery of Human MERTK Provides Long-Term Retinal Preservation in RCS Rats
Deng, W.-T., Dinculescu, A., Li, Q., Boye, S. L., Li, J., Gorbatyuk, M. S., Pang, J., Chiodo, V. A., Matthes, M. T., Yasumura, D., et al. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.11-8831 · Cited by 55
Coluccio, A., Miselli, F., Lombardo, A., Marconi, A., Malagoli Tagliazucchi, G., Gonçalves, M. A., Pincelli, C., Maruggi, G., Del Rio, M., Naldini, L., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.143 · Cited by 55
Immune barriers to successful gene therapy
Wu, T.-L., & Ertl, H. C. J. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.11.005 · Cited by 57
Gene therapy provides long-term visual function in a pre-clinical model of retinitis pigmentosa
Wert, K. J., Davis, R. J., Sancho-Pelluz, J., Nishina, P. M., & Tsang, S. H. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds466 · Cited by 55
The genetic profile of Leber congenital amaurosis in an Australian cohort
Thompson, J. A., Roach, J. N. D., McLaren, T. L., Montgomery, H. E., Hoffmann, L., Campbell, I., Chen, F. K., Mackey, D. A., & Lamey, T. M. (2017) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.321 · Cited by 60
“…strategies (antisense oligonucleotides [AONs]/translational-read-through-inducing drugs) (Bainbridge et al. 2008; Hauswirth et al. 2008; Maguire et al. 2008; Goldmann et al. 2010; Collin et al. 2012; Gerard et al. 2012; Koenekoop et al. 2014; Schwarz et al. 2015; Garanto et al. 2016;…”
BackgroundTherapeutic strategy to rescue mutation-induced exon skipping in rhodopsin by adaptation of U1 snRNA
Tanner, G., Glaus, E., Barthelmes, D., Ader, M., Fleischhauer, J. C., Pagani, F., Berger, W., & Neidhardt, J. (2008) · Human Mutation · doi:10.1002/humu.20861 · Cited by 59
“Even more significantly, AAV-mediated delivery of RPE65 to human retina improved retinal function of patients suffering from Leber congenital amaurosis without showing any significant adverse effect [Bainbridge et al., 2008; Maguire et al., 2008].”
BackgroundHarbison, C. E., Weichert, W. S., Gurda, B. L., Chiorini, J. A., Agbandje-McKenna, M., & Parrish, C. R. (2012) · Journal of General Virology · doi:10.1099/vir.0.035113-0 · Cited by 54
“Successful outcomes of AAV gene delivery have also been realized by direct injection into partially immune privileged tissues such as the retinal pigment epithelium (Maguire et al., 2008).”
BackgroundHumoral immune responses to AAV gene therapy in the ocular compartment
Whitehead, M., Osborne, A., Yu‐Wai‐Man, P., & Martin, K. (2021) · Biological Reviews · doi:10.1111/brv.12718 · Cited by 52
Subretinal therapy: technological solutions to surgical and immunological challenges
Ladha, R., Caspers, L. E., Willermain, F., & de Smet, M. D. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.846782 · Cited by 54
Wang, L.-N., Wang, Y., Lu, Y., Yin, Z.-F., Zhang, Y.-H., Aslanidi, G., Srivastava, A., Ling, C., & Ling, C. (2014) · Journal of Chinese Integrative Medicine · doi:10.1016/s2095-4964(14)60003-0 · Cited by 54
LaLumiere, R. T. (2010) · Brain stimulation · doi:10.1016/j.brs.2010.09.009 · Cited by 63
“In recent trials, AAV-mediated gene therapy has been shown to be at least modestly effective and safe.(12,13,28,29) Although AAV is generally considered unlikely to produce immune responses, it should be noted that it is capable of eliciting an immune response in the brain and, thus, work must be monitored for such sa…”
MethodGene-based therapies for dominantly inherited retinopathies
Farrar, G. J., Millington‐Ward, S., Chadderton, N., Humphries, P., & Kenna, P. F. (2011) · Gene Therapy · doi:10.1038/gt.2011.172 · Cited by 62
Song, L., Li, X., Jayandharan, G. R., Wang, Y., Aslanidi, G. V., Ling, C., Zhong, L., Gao, G., Yoder, M. C., Ling, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058757 · Cited by 54
Nistor, G., Seiler, M. J., Yan, F., Ferguson, D. J. P., & Keirstead, H. S. (2010) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2010.04.025 · Cited by 65
Optogenetic Approaches to Restoring Vision
Pan, Z., Lu, Q., Bi, A., Dizhoor, A. M., & Abrams, G. W. (2015) · Annual Review of Vision Science · doi:10.1146/annurev-vision-082114-035532 · Cited by 58
Boisgerault, F., & Mingozzi, F. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150630121750 · Cited by 54
Self-citationGene Therapy in a Large Animal Model of PDE6A-Retinitis Pigmentosa
Mowat, F. M., Occelli, L. M., Bartoe, J. T., Gervais, K. J., Bruewer, A. R., Querubin, J., Dinculescu, A., Boye, S. L., Hauswirth, W. W., & Petersen-Jones, S. M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00342 · Cited by 53
“…the safety and efficacy of gene augmentation using adeno-associated viral vectors in patients with Leber Congenital Amaurosis due to RPE65 gene mutations (Bainbridge et al., 2008; Cideciyan et al., 2008, 2009a,b; Hauswirth et al., 2008; Maguire et al., 2008, 2009; Simonelli et al., 2010).”
BackgroundInfluentialØstergaard, E., Dunø, M., Batbayli, M., Vilhelmsen, K., & Rosenberg, T. (2011) · PubMed Central · Cited by 60
Recombinant Adeno-Associated Viral Vector Production and Purification
Shin, J.-H., Yue, Y., & Duan, D. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-343-1_15 · Cited by 54
Charbel Issa, P., De Silva, S. R., Lipinski, D. M., Singh, M. S., Mouravlev, A., You, Q., Barnard, A. R., Hankins, M. W., During, M. J., & MacLaren, R. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060361 · Cited by 53
“Recent developments in retinal gene therapy have led to the successful treatment of patients with Leber’s congenital amaurosis (LCA) due to mutations in RPE65 [1,2,3,4,5,6,7].”
Yang, R., Zhao, P., Wang, L., Feng, C., Chen, P., Wang, Z., Zhang, Y., Shen, M., Shi, K., Weng, S.-J., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01137-8 · Cited by 62
AAV-mediated knockdown of Peripherin-2 in vivo using miRNA-based hairpins
Georgiadis, A., Tschernutter, M., Bainbridge, J. W., Robbie, S. J., McIntosh, J., Nathwani, A. C., Smith, A. J., & Ali, R. R. (2009) · Gene Therapy · doi:10.1038/gt.2009.162 · Cited by 58
Leborgne, C., Latournerie, V., Boutin, S., Desgue, D., Quéré, A., Pignot, E., Collaud, F., Charles, S., Simon Sola, M., Masat, E., et al. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2018.03.004 · Cited by 53
“AAV gene transfer has resulted in several examples of success in human trials [7-14].”
BackgroundSelf-citationMcDougald, D. S., Dine, K. E., Zezulin, A. U., Bennett, J., & Shindler, K. S. (2018) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22972 · Cited by 53
Self-citationThe Future Looks Brighter After 25 Years of Retinal Gene Therapy
Auricchio, A., Smith, A. J., & Ali, R. R. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.164 · Cited by 52
“The trials, two in the US and one in the UK, showed that AAV‐mediated gene therapy could be safe and effective, with improvements in visual acuity, pupillary reflex, light sensitivity and ability to navigate in dim light.(17,18,19) Therapeutic benefit was observed several weeks after injection and at least some benefi…”
Self-citationKong, F., Li, W., Li, X., Zheng, Q., Dai, X., Zhou, X., Boye, S. L., Hauswirth, W. W., Qu, J., & Pang, J.-J. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.01.011 · Cited by 51
“, 2000), and utilizing a shortened version of a promoter, chimeric CMVchicken beta-actin (CBA), which is reported to be safe, effective and persistent when used in proof of concept experiments and clinical trials of retinal disease (Bainbridge et al., 2008; Maguire et al., 2008; Cideciyan et al., 2008; Cideciyan et al…”
BackgroundInfluentialAdenoviral vector-mediated gene therapy for gliomas: coming of age
Castro, M. G., Candolfi, M., Wilson, T. J., Calinescu, A., Paran, C. W., Kamran, N., Koschmann, C. J., Moreno-Ayala, M. A., Assi, H. H., & Lowenstein, P. R. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.915307 · Cited by 56
“AAV vectors have enjoyed recent success in the treatment of inherited eye diseases [114], while lentiviral vectors, building on the strong record of retrovirus, have made gene transfer into the bone marrow safer and more effective [115,116].”
BackgroundFradot, M., Busskamp, V., Forster, V., Cronin, T., Léveillard, T., Bennett, J., Sahel, J.-A., Roska, B., & Picaud, S. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.157 · Cited by 51
“Recent clinical trials have validated gene therapy for the treatment of an inherited blinding disease previously considered incurable (Bainbridge and Ali, 2008; Cideciyan et al., 2008; Maguire et al., 2008).”
Self-citationLipophosphonate/lipophosphoramidates: A family of synthetic vectors efficient for gene delivery
Berchel, M., Gall, T. L., Couthon‐Gourvès, H., Haelters, J., Montier, T., Midoux, P., Lehn, P., & Jaffrès, P. (2011) · Biochimie · doi:10.1016/j.biochi.2011.07.026 · Cited by 55
Gearhart, P. M. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.210 · Cited by 52
Askou, A. L., Aagaard, L., Kostic, C., Arsenijevic, Y., Hollensen, A. K., Bek, T., Jensen, T. G., Mikkelsen, J. G., & Corydon, T. J. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.64 · Cited by 52
A Large Animal Model for CNGB1 Autosomal Recessive Retinitis Pigmentosa
Winkler, P. A., Ekenstedt, K. J., Occelli, L. M., Frattaroli, A. V., Bartoe, J. T., Venta, P. J., & Petersen‐Jones, S. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072229 · Cited by 54
“For example, dogs with a mutation in RPE65 as a model for Leber congenital amaurosis type II were crucial for preclinical proof-of-concept gene therapy trials [19] which led to phase 1/2 human clinical trials [20,21,22].”
BackgroundRoca, C., Motas, S., Marcó, S., Ribera, A., Sánchez, V., Sánchez, X., Bertolin, J., León, X., Pérez, J., Garcia, M., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx058 · Cited by 60
Optimization of AAV vectors to target persistent viral reservoirs
Colón-Thillet, R., Jerome, K. R., & Stone, D. (2021) · Virology Journal · doi:10.1186/s12985-021-01555-7 · Cited by 50
A wise consistency: engineering biology for conformity, reliability, predictability
Arkin, A. P. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.09.012 · Cited by 61
Electrical activity enhances neuronal survival and regeneration
Corredor, R. G., & Goldberg, J. L. (2009) · Journal of Neural Engineering · doi:10.1088/1741-2560/6/5/055001 · Cited by 55
A mutation in gene CNGA3 is associated with day blindness in sheep
Reicher, S., Seroussi, E., & Gootwine, E. (2009) · Genomics · doi:10.1016/j.ygeno.2009.10.003 · Cited by 54
“As gene therapy is becoming a real possibility for treating retinal genetic illnesses [30–32], sheep homozygous for the CNGA3 mutation may serve as an animal model for studying and treating this illness in humans.”
BackgroundCurrent Concepts in the Treatment of Retinitis Pigmentosa
Musarella, M. A., & MacDonald, I. M. (2010) · Journal of Ophthalmology · doi:10.1155/2011/753547 · Cited by 61
“[14] first described separate clinical trials investigating the short-term safety and preliminary efficacy of OGT for LCA in humans.”
BackgroundMethodInfluentialSchievenbusch, S., Strack, I., Scheffler, M., Nischt, R., Coutelle, O., Hösel, M., Hallek, M. J., Fries, J., Dienes, H., Odenthal, M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.71 · Cited by 55
Treatment of a retinal dystrophy, fundus albipunctatus, with oral 9-cis- -carotene
Rotenstreich, Y., Harats, D., Shaish, A., Pras, E., & Belkin, M. (2010) · British Journal of Ophthalmology · doi:10.1136/bjo.2009.167049 · Cited by 51
“As far as we are aware, there is no reported treatment demonstrating a significant improvement in retinal functions in patients with retinal dystrophy.(24) 25 Our results suggest that 9-cis-b-carotene, in the form of the food supplement tested in this pilot trial, is likely to provide at least some benefit in patients…”
Identification of an adeno-associated virus binding epitope for AVB sepharose affinity resin
Wang, Q., Lock, M., Prongay, A. J., Alvira, M. R., Petkov, B., & Wilson, J. M. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.40 · Cited by 50
Pharmacotherapy of retinal disease with visual cycle modulators
Hussain, R. M., Gregori, N. Z., Ciulla, T. A., & Lam, B. L. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1448060 · Cited by 56
Regenerative medicine in the retina: from stem cells to cell replacement therapy
Oswald, J., & Baranov, P. Y. (2018) · Therapeutic Advances in Ophthalmology · doi:10.1177/2515841418774433 · Cited by 54
AAV serotype influences gene transfer in corneal stroma in vivo
Sharma, A., Tovey, J. C. K., Ghosh, A., & Mohan, R. R. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.06.020 · Cited by 51
The Genomic Response of the Retinal Pigment Epithelium to Light Damage and Retinal Detachment
Rattner, A., Toulabi, L., Williams, J., Yu, H., & Nathans, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2401-08.2008 · Cited by 50
“The viral gene transfer strategy has been used in Rpe65 deficient rodent and dogs (Bennicelli et al., 2008), and it is currently in human clinical trials (Bainbridge et al., 2008; Maguire et al., 2008).”
BackgroundMethodNon-viral therapeutic approaches to ocular diseases: An overview and future directions
Zulliger, R., Conley, S. M., & Naash, M. I. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.007 · Cited by 50
“Patients were treated with AAV containing the RPE65 cDNA and either a ubiquitously expressed promoter or the native RPE65 promoter(45-48).”
MethodSharma, A., Ghosh, A., Hansen, E. T., Newman, J. M., & Mohan, R. R. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.07.005 · Cited by 55
“Further, AAV2 has been widely used in preclinical and clinical trials for many retinal diseases including ocular albinism, retinitis pigmentosa and Leber congenital amaurosis [3,16,25].”
Peng, C., Cherng, J., Chiou, G., Chen, Y., Chien, C.-H., Kao, C.-L., Chang, Y.-L., Chien, Y., Chen, L., Liu, J., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.08.008 · Cited by 54
The eye as a model of ageing in translational research – Molecular, epigenetic and clinical aspects
Pathai, S., Shiels, P. G., Lawn, S. D., Cook, C., & Gilbert, C. E. (2012) · Ageing Research Reviews · doi:10.1016/j.arr.2012.11.002 · Cited by 54
Gene Therapy of Inherited Retinopathies: A Long and Successful Road from Viral Vectors to Patients
Colella, P., & Auricchio, A. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.123 · Cited by 50
“…NCT00516477, NCT00481546) by SR delivery of AAV2/2 encoding for the human RPE65 gene (Bainbridge et al., 2008; Cideciyan et al., 2008, 2009a,b; Hauswirth et al., 2008; Maguire et al., 2008, 2009; Simonelli et al., 2010; Ashtari et al., 2011; Bennett et al., 2012; Jacobson et al., 2012) (Table 1).”
BackgroundMethodInfluentialSelf-citationSimunovic, M. P., Xue, K., Jolly, J. K., & MacLaren, R. E. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.5630 · Cited by 50
Ferla, R., Alliegro, M., Marteau, J., Dell’Anno, M., Nusco, E., Pouillot, S., Galimberti, S., Valsecchi, M. G., Zuliani, V., & Auricchio, A. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.07.004 · Cited by 51
Self-citationOptimization of DNA delivery by three classes of hybrid nanoparticle/DNA complexes
Zhong, Q., Chinta, D. M. D., Pamujula, S., Wang, H., Yao, X., Mandal, T. K., & Luftig, R. B. (2010) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-8-6 · Cited by 50
“All four approaches are non-toxic and have dominated viral gene therapy efforts in clinical trials and animal models [1-6].”
BackgroundConvergence of Human Genetics and Animal Studies: Gene Therapy for X-Linked Retinoschisis
Bush, R. A., Wei, L. L., & Sieving, P. A. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017368 · Cited by 50
“…pigmentation, vision/eye Cite this article as Cold Spring Harb Perspect Med 2015;5:a017368 5 w w w .p er sp ec ti ve si n m ed ic in e. o rg et al. 2005; Campochiaro et al. 2006; Bainbridge et al. 2008; Hauswirth et al. 2008; Maguire et al. 2008, 2009; Simonelli et al. 2010; Balaggan and Ali 2012).”
BackgroundCwerman-Thibault, H., Augustin, S., Ellouze, S., Sahel, J.-A., & Corral-Debrinski, M. (2014) · Comptes Rendus. Biologies · doi:10.1016/j.crvi.2013.11.011 · Cited by 49
Personalized therapeutic strategies for patients with retinitis pigmentosa
Zheng, A., Li, Y., & Tsang, S. H. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1006192 · Cited by 60
“Landmark Phase I/II human clinical trials of RPE65 gene therapy for RPE65-related early onset retinal dystrophy, a form of RP, successfully rescued visual function and improved pupillary light reflex and full-field sensitivity in a small group of pediatric patients [11-14].”
BackgroundWang, J.-H., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.017 · Cited by 53
Advances in repairing the degenerate retina by rod photoreceptor transplantation
Pearson, R. A. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.01.001 · Cited by 54
Promising and delivering gene therapies for vision loss
Carvalho, L. S., & Vandenberghe, L. H. (2015) · Vision Research · doi:10.1016/j.visres.2014.07.013 · Cited by 49
Vincent, A., Wright, T., Garcia-Sanchez, Y., Kisilak, M. L., Campbell, M. C. W., Westall, C. A., & Héon, E. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-10971 · Cited by 47
Zhong, L., Malani, N., Li, M., Brady, T., Xie, J., Bell, P., Li, S., Jones, H., Wilson, J. M., Flotte, T. R., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.112 · Cited by 49
“rAAV-based vectors are presently in use in human clinical trials to treat cystic fibrosis, a-1 anti-trypsin deficiency, Parkinson’s disease, Batten’s disease, muscular dystrophy, Leber’s congenital amaurosis, and hemophilia B (Flotte et al., 2004; Mandel et al., 2006; Kaplitt et al., 2007; Maguire et al., 2008; Worgal…”
Treharne, A. J., Grossel, M. C., Lotery, A. J., & Thomson, H. A. (2010) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.184002 · Cited by 55
Yzer, S., den Hollander, A. I., López, I., Pott, J.-W. R., de Faber, J. T., Cremers, F. P. M., Koenekoop, R. K., & van den Born, L. I. (2012) · PubMed · Cited by 58
Pathways and disease-causing alterations in visual chromophore production for vertebrate vision
Kiser, P. D., & Palczewski, K. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.014405 · Cited by 53
“However, clinical trials on RPE65 gene augmentation therapy showed only a modest improvement in retinal function (112, 113) and fading effects in patients (114).”
BackgroundAAV‐mediated gene delivery in Dp71‐null mouse model with compromised barriers
Vacca, O., Darche, M., Schaffer, D. V., Flannery, J. G., Sahel, J., Rendon, A., & Dalkara, D. (2014) · Glia · doi:10.1002/glia.22617 · Cited by 48
Nicolson, S. C., Li, C., Hirsch, M. L., Setola, V., & Samulski, R. J. (2016) · Journal of Virology · doi:10.1128/jvi.02953-15 · Cited by 48
Therapy with voretigene neparvovec. How to measure success?
Stingl, K., Kempf, M., Jung, R., Kortüm, F., Righetti, G., Reith, M., Dimopoulos, S., Ott, S., Kohl, S., & Stingl, K. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101115 · Cited by 48
Koilkonda, R. D. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.135 · Cited by 48
“Unlike electroporation of plasmid DNA that provides transient low-efficiency ocular gene expression and thus is not suitable for treatment of patients with LHON, gene delivery with the AAV vector is highly efficient and stable for years, and AAV has a proven track record in human clinical trials in the eye.(10,11,32,3…”
BackgroundMethodLi, C., Wu, S., Albright, B., Hirsch, M., Li, W., Tseng, Y.-S., Agbandje-McKenna, M., McPhee, S., Asokan, A., & Samulski, R. J. (2016) · Molecular Therapy · doi:10.1038/mt.2015.134 · Cited by 48
Metadata
- Authors
- Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., Rossi, S., Lyubarsky, A., Arruda, V. R., Konkle, B., Stone, E., Sun, J., Jacobs, J., Dell'Osso, L., Hertle, R., Ma, J.-X., Redmond, T. M., Zhu, X., Hauck, B., Zelenaia, O., Shindler, K. S., Maguire, M. G., Wright, J. F., Volpe, N. J., McDonnell, J. W., Auricchio, A., High, K. A., & Bennett, J.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Telethon Institute Of Genetics And Medicine (IT)
- University of Pennsylvania (US)
- University of Iowa (US)
- Veterans Health Administration (US)
- Children's Hospital of Pittsburgh (US)
- University of Oklahoma (US)
- National Eye Institute (US)
- ORCID
- Maguire, Albert M.
- Simonelli, Francesca
- Pierce, Eric A.
- Pugh, Edward N.
- Mingozzi, Federico
- Banfi, Sandro
- Testa, Francesco
- Surace, Enrico M.
- Rossi, Settimio
- Arruda, Valder R.
- Konkle, Barbara
- Stone, Edwin
- Sun, Junwei
- Hertle, Richard
- Ma, Jian-xing
- Redmond, T. Michael
- Zhu, Xiaosong
- Shindler, Kenneth S.
- Maguire, Maureen G.
- Wright, J. Fraser
- Volpe, Nicholas J.
- Auricchio, Alberto
- High, Katherine A.
- Bennett, Jean
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-22
- Volume
- 358
- Issue
- 21
- Pages
- 2240-2248
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2829748
- OpenAlex
- W2137222303
- Cited by
- 2,145
- References
- 27
- Citations by year
- 2026: 38 · 2025: 68 · 2024: 51 · 2023: 66 · 2022: 79 · 2021: 110 · 2020: 96 · 2019: 98 · 2018: 118 · 2017: 144 · 2016: 124 · 2015: 172 · 2014: 152 · 2013: 155 · 2012: 158
- FWCI
- 70.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Eye Institute (EY10820, R01EY010820)
- National Center for Research Resources (UL1RR024134)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- Leber congenital amaurosis, RPE65, gene therapy, adeno-associated virus vectors, retinal pigment epithelium, macular hole, visual acuity, retinal function, adverse events, inherited retinal degeneration
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Adult, Blindness, Carrier Proteins, Eye Proteins, Genetic Vectors, Humans, Injections, Mutation, Promoter Regions, Genetic, Reflex, Pupillary, Retina, Retinal Degeneration, Visual Acuity, Genetic Therapy, Gene Transfer Techniques, DNA, Complementary, cis-trans-Isomerases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.